NASDAQ:EGRX

Eagle Pharmaceuticals Competitors

$44.27
-0.04 (-0.09 %)
(As of 04/16/2021 04:00 PM ET)
Add
Compare
Today's Range
$44.20
Now: $44.27
$44.96
50-Day Range
$39.63
MA: $43.08
$45.98
52-Week Range
$36.48
Now: $44.27
$56.16
Volume111,947 shs
Average Volume124,162 shs
Market Capitalization$585.12 million
P/E Ratio126.49
Dividend YieldN/A
Beta0.74

Competitors

Eagle Pharmaceuticals (NASDAQ:EGRX) Vs. PBH, DRNA, ZNTL, NGM, MDGL, and AXSM

Should you be buying EGRX stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Eagle Pharmaceuticals, including Prestige Consumer Healthcare (PBH), Dicerna Pharmaceuticals (DRNA), Zentalis Pharmaceuticals (ZNTL), NGM Biopharmaceuticals (NGM), Madrigal Pharmaceuticals (MDGL), and Axsome Therapeutics (AXSM).

Prestige Consumer Healthcare (NYSE:PBH) and Eagle Pharmaceuticals (NASDAQ:EGRX) are both consumer discretionary companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, valuation, analyst recommendations, earnings, institutional ownership and profitability.

Analyst Ratings

This is a summary of current ratings and recommmendations for Prestige Consumer Healthcare and Eagle Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Prestige Consumer Healthcare03302.50
Eagle Pharmaceuticals01002.00

Prestige Consumer Healthcare presently has a consensus price target of $87.60, suggesting a potential upside of 93.72%. Eagle Pharmaceuticals has a consensus price target of $46.00, suggesting a potential upside of 3.91%. Given Prestige Consumer Healthcare's stronger consensus rating and higher possible upside, equities research analysts plainly believe Prestige Consumer Healthcare is more favorable than Eagle Pharmaceuticals.

Risk and Volatility

Prestige Consumer Healthcare has a beta of 0.76, meaning that its share price is 24% less volatile than the S&P 500. Comparatively, Eagle Pharmaceuticals has a beta of 0.74, meaning that its share price is 26% less volatile than the S&P 500.

Earnings and Valuation

This table compares Prestige Consumer Healthcare and Eagle Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Prestige Consumer Healthcare$963.01 million2.34$142.28 million$2.9615.28
Eagle Pharmaceuticals$195.89 million2.99$14.31 million$1.3832.08

Prestige Consumer Healthcare has higher revenue and earnings than Eagle Pharmaceuticals. Prestige Consumer Healthcare is trading at a lower price-to-earnings ratio than Eagle Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

95.1% of Eagle Pharmaceuticals shares are held by institutional investors. 1.2% of Prestige Consumer Healthcare shares are held by insiders. Comparatively, 21.1% of Eagle Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Prestige Consumer Healthcare and Eagle Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Prestige Consumer Healthcare17.03%13.76%4.80%
Eagle Pharmaceuticals2.65%8.50%5.44%

Summary

Prestige Consumer Healthcare beats Eagle Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

Dicerna Pharmaceuticals (NASDAQ:DRNA) and Eagle Pharmaceuticals (NASDAQ:EGRX) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, institutional ownership and risk.

Institutional and Insider Ownership

80.6% of Dicerna Pharmaceuticals shares are owned by institutional investors. Comparatively, 95.1% of Eagle Pharmaceuticals shares are owned by institutional investors. 11.3% of Dicerna Pharmaceuticals shares are owned by insiders. Comparatively, 21.1% of Eagle Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Dicerna Pharmaceuticals and Eagle Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Dicerna Pharmaceuticals-88.81%-71.72%-16.60%
Eagle Pharmaceuticals2.65%8.50%5.44%

Volatility and Risk

Dicerna Pharmaceuticals has a beta of 1.33, indicating that its share price is 33% more volatile than the S&P 500. Comparatively, Eagle Pharmaceuticals has a beta of 0.74, indicating that its share price is 26% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and price targets for Dicerna Pharmaceuticals and Eagle Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Dicerna Pharmaceuticals00703.00
Eagle Pharmaceuticals01002.00

Dicerna Pharmaceuticals currently has a consensus target price of $39.1429, suggesting a potential upside of 35.16%. Eagle Pharmaceuticals has a consensus target price of $46.00, suggesting a potential upside of 3.91%. Given Dicerna Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts clearly believe Dicerna Pharmaceuticals is more favorable than Eagle Pharmaceuticals.

Valuation & Earnings

This table compares Dicerna Pharmaceuticals and Eagle Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Dicerna Pharmaceuticals$23.90 million92.48$-120,460,000.00($1.76)-16.45
Eagle Pharmaceuticals$195.89 million2.99$14.31 million$1.3832.08

Eagle Pharmaceuticals has higher revenue and earnings than Dicerna Pharmaceuticals. Dicerna Pharmaceuticals is trading at a lower price-to-earnings ratio than Eagle Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Eagle Pharmaceuticals beats Dicerna Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) and Eagle Pharmaceuticals (NASDAQ:EGRX) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, earnings, risk, analyst recommendations, institutional ownership, dividends and valuation.

Institutional & Insider Ownership

67.1% of Zentalis Pharmaceuticals shares are held by institutional investors. Comparatively, 95.1% of Eagle Pharmaceuticals shares are held by institutional investors. 21.1% of Eagle Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Zentalis Pharmaceuticals and Eagle Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Zentalis PharmaceuticalsN/AN/AN/A
Eagle Pharmaceuticals2.65%8.50%5.44%

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Zentalis Pharmaceuticals and Eagle Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Zentalis Pharmaceuticals00703.00
Eagle Pharmaceuticals01002.00

Zentalis Pharmaceuticals presently has a consensus target price of $56.4286, suggesting a potential upside of 11.34%. Eagle Pharmaceuticals has a consensus target price of $46.00, suggesting a potential upside of 3.91%. Given Zentalis Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe Zentalis Pharmaceuticals is more favorable than Eagle Pharmaceuticals.

Valuation and Earnings

This table compares Zentalis Pharmaceuticals and Eagle Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Zentalis PharmaceuticalsN/AN/AN/AN/AN/A
Eagle Pharmaceuticals$195.89 million2.99$14.31 million$1.3832.08

Eagle Pharmaceuticals has higher revenue and earnings than Zentalis Pharmaceuticals.

Summary

Eagle Pharmaceuticals beats Zentalis Pharmaceuticals on 6 of the 9 factors compared between the two stocks.

NGM Biopharmaceuticals (NASDAQ:NGM) and Eagle Pharmaceuticals (NASDAQ:EGRX) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, earnings, risk, analyst recommendations, institutional ownership, dividends and valuation.

Institutional & Insider Ownership

49.6% of NGM Biopharmaceuticals shares are held by institutional investors. Comparatively, 95.1% of Eagle Pharmaceuticals shares are held by institutional investors. 50.4% of NGM Biopharmaceuticals shares are held by insiders. Comparatively, 21.1% of Eagle Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares NGM Biopharmaceuticals and Eagle Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NGM Biopharmaceuticals$103.54 million19.37$-42,790,000.00($0.85)-30.76
Eagle Pharmaceuticals$195.89 million2.99$14.31 million$1.3832.08

Eagle Pharmaceuticals has higher revenue and earnings than NGM Biopharmaceuticals. NGM Biopharmaceuticals is trading at a lower price-to-earnings ratio than Eagle Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

NGM Biopharmaceuticals has a beta of 1.97, indicating that its stock price is 97% more volatile than the S&P 500. Comparatively, Eagle Pharmaceuticals has a beta of 0.74, indicating that its stock price is 26% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for NGM Biopharmaceuticals and Eagle Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
NGM Biopharmaceuticals00523.29
Eagle Pharmaceuticals01002.00

NGM Biopharmaceuticals presently has a consensus target price of $39.1111, suggesting a potential upside of 49.56%. Eagle Pharmaceuticals has a consensus target price of $46.00, suggesting a potential upside of 3.91%. Given NGM Biopharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe NGM Biopharmaceuticals is more favorable than Eagle Pharmaceuticals.

Profitability

This table compares NGM Biopharmaceuticals and Eagle Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
NGM Biopharmaceuticals-91.64%-29.47%-25.58%
Eagle Pharmaceuticals2.65%8.50%5.44%

Summary

Eagle Pharmaceuticals beats NGM Biopharmaceuticals on 8 of the 15 factors compared between the two stocks.

Eagle Pharmaceuticals (NASDAQ:EGRX) and Madrigal Pharmaceuticals (NASDAQ:MDGL) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, analyst recommendations, profitability, earnings and valuation.

Insider and Institutional Ownership

95.1% of Eagle Pharmaceuticals shares are held by institutional investors. Comparatively, 74.2% of Madrigal Pharmaceuticals shares are held by institutional investors. 21.1% of Eagle Pharmaceuticals shares are held by company insiders. Comparatively, 41.9% of Madrigal Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Eagle Pharmaceuticals and Madrigal Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Eagle Pharmaceuticals$195.89 million2.99$14.31 million$1.3832.08
Madrigal PharmaceuticalsN/AN/A$-83,950,000.00($5.45)-22.89

Eagle Pharmaceuticals has higher revenue and earnings than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Eagle Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Eagle Pharmaceuticals has a beta of 0.74, suggesting that its share price is 26% less volatile than the S&P 500. Comparatively, Madrigal Pharmaceuticals has a beta of 1.19, suggesting that its share price is 19% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings for Eagle Pharmaceuticals and Madrigal Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Eagle Pharmaceuticals01002.00
Madrigal Pharmaceuticals03702.70

Eagle Pharmaceuticals presently has a consensus price target of $46.00, suggesting a potential upside of 3.91%. Madrigal Pharmaceuticals has a consensus price target of $167.60, suggesting a potential upside of 34.33%. Given Madrigal Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Madrigal Pharmaceuticals is more favorable than Eagle Pharmaceuticals.

Profitability

This table compares Eagle Pharmaceuticals and Madrigal Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Eagle Pharmaceuticals2.65%8.50%5.44%
Madrigal PharmaceuticalsN/A-47.64%-43.21%

Summary

Eagle Pharmaceuticals beats Madrigal Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

Eagle Pharmaceuticals (NASDAQ:EGRX) and Axsome Therapeutics (NASDAQ:AXSM) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, analyst recommendations, profitability, earnings and valuation.

Profitability

This table compares Eagle Pharmaceuticals and Axsome Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Eagle Pharmaceuticals2.65%8.50%5.44%
Axsome TherapeuticsN/A-62.33%-47.87%

Valuation & Earnings

This table compares Eagle Pharmaceuticals and Axsome Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Eagle Pharmaceuticals$195.89 million2.99$14.31 million$1.3832.08
Axsome TherapeuticsN/AN/A$-68,350,000.00($2.01)-26.59

Eagle Pharmaceuticals has higher revenue and earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Eagle Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Eagle Pharmaceuticals has a beta of 0.74, suggesting that its share price is 26% less volatile than the S&P 500. Comparatively, Axsome Therapeutics has a beta of 2.59, suggesting that its share price is 159% more volatile than the S&P 500.

Insider and Institutional Ownership

95.1% of Eagle Pharmaceuticals shares are held by institutional investors. Comparatively, 63.6% of Axsome Therapeutics shares are held by institutional investors. 21.1% of Eagle Pharmaceuticals shares are held by company insiders. Comparatively, 26.0% of Axsome Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings for Eagle Pharmaceuticals and Axsome Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Eagle Pharmaceuticals01002.00
Axsome Therapeutics101002.82

Eagle Pharmaceuticals presently has a consensus price target of $46.00, suggesting a potential upside of 3.91%. Axsome Therapeutics has a consensus price target of $152.6667, suggesting a potential upside of 185.68%. Given Axsome Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Axsome Therapeutics is more favorable than Eagle Pharmaceuticals.

Summary

Eagle Pharmaceuticals beats Axsome Therapeutics on 8 of the 13 factors compared between the two stocks.


Eagle Pharmaceuticals Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Prestige Consumer Healthcare logo
PBH
Prestige Consumer Healthcare
1.6$45.22-0.4%$2.25 billion$963.01 million14.04
Dicerna Pharmaceuticals logo
DRNA
Dicerna Pharmaceuticals
2.0$28.96-1.5%$2.21 billion$23.90 million-17.99Analyst Report
Unusual Options Activity
News Coverage
Gap Down
Zentalis Pharmaceuticals logo
ZNTL
Zentalis Pharmaceuticals
1.6$50.68-0.8%$2.08 billionN/A0.00Insider Selling
Analyst Revision
NGM Biopharmaceuticals logo
NGM
NGM Biopharmaceuticals
1.8$26.15-0.3%$2.01 billion$103.54 million-19.66Insider Selling
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.7$124.77-1.5%$2.00 billionN/A-11.27
Axsome Therapeutics logo
AXSM
Axsome Therapeutics
1.4$53.44-1.6%$2.00 billionN/A-19.87
Amarin logo
AMRN
Amarin
1.6$5.02-0.2%$1.98 billion$429.76 million-100.38Analyst Revision
Revance Therapeutics logo
RVNC
Revance Therapeutics
1.7$27.22-3.5%$1.94 billion$410,000.00-5.92Analyst Report
IGM Biosciences logo
IGMS
IGM Biosciences
1.7$59.69-4.6%$1.91 billionN/A-25.40Increase in Short Interest
MacroGenics logo
MGNX
MacroGenics
1.2$31.83-2.4%$1.91 billion$64.19 million-10.17Decrease in Short Interest
News Coverage
Seres Therapeutics logo
MCRB
Seres Therapeutics
1.7$20.73-3.2%$1.90 billion$34.51 million-17.72
Kura Oncology logo
KURA
Kura Oncology
1.6$28.59-3.1%$1.89 billionN/A-17.54
FibroGen logo
FGEN
FibroGen
1.8$19.91-3.1%$1.82 billion$256.58 million-7.63Analyst Report
High Trading Volume
News Coverage
MORF
Morphic
1.3$55.08-0.6%$1.79 billion$16.98 million-35.31Insider Selling
Decrease in Short Interest
Pandion Therapeutics logo
PAND
Pandion Therapeutics
1.0$60.05-0.0%$1.77 billion$970,000.000.00
Five Prime Therapeutics logo
FPRX
Five Prime Therapeutics
1.4$38.00-0.0%$1.77 billion$14.87 million-14.18Increase in Short Interest
News Coverage
Cytokinetics logo
CYTK
Cytokinetics
1.7$24.70-0.7%$1.77 billion$26.87 million-12.93Insider Selling
Amneal Pharmaceuticals logo
AMRX
Amneal Pharmaceuticals
1.8$5.89-0.2%$1.77 billion$1.63 billion14.37Analyst Report
Decrease in Short Interest
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.6$10.61-2.2%$1.71 billion$428.41 million15.38News Coverage
Supernus Pharmaceuticals logo
SUPN
Supernus Pharmaceuticals
1.5$31.70-0.5%$1.68 billion$392.76 million13.15Analyst Upgrade
Analyst Revision
Myovant Sciences logo
MYOV
Myovant Sciences
1.3$18.06-1.0%$1.64 billionN/A-6.43Increase in Short Interest
Heron Therapeutics logo
HRTX
Heron Therapeutics
1.7$17.87-0.8%$1.63 billion$145.97 million-7.23
ADC Therapeutics logo
ADCT
ADC Therapeutics
1.7$23.29-1.4%$1.60 billion$2.34 million-9.87
Harmony Biosciences logo
HRMY
Harmony Biosciences
1.4$28.15-0.5%$1.60 billionN/A0.00Analyst Revision
News Coverage
Generation Bio logo
GBIO
Generation Bio
1.8$28.30-2.8%$1.60 billionN/A0.00Insider Selling
Increase in Short Interest
Aurinia Pharmaceuticals logo
AUPH
Aurinia Pharmaceuticals
1.8$12.35-2.0%$1.57 billion$320,000.00-8.40News Coverage
uniQure logo
QURE
uniQure
1.7$34.07-4.1%$1.53 billion$7.28 million-9.04Insider Selling
Travere Therapeutics logo
TVTX
Travere Therapeutics
1.2$24.95-4.0%$1.51 billion$175.34 million-14.68Analyst Downgrade
Analyst Revision
News Coverage
ImmunoGen logo
IMGN
ImmunoGen
1.5$7.52-2.4%$1.50 billion$82.27 million-18.34
Prelude Therapeutics logo
PRLD
Prelude Therapeutics
1.4$32.24-5.2%$1.50 billionN/A0.00Analyst Upgrade
News Coverage
Applied Molecular Transport logo
AMTI
Applied Molecular Transport
2.0$41.84-3.6%$1.47 billionN/A0.00
OLMA
Olema Pharmaceuticals
1.6$36.14-2.1%$1.45 billionN/A0.00Increase in Short Interest
News Coverage
PMV Pharmaceuticals logo
PMVP
PMV Pharmaceuticals
1.4$32.37-0.9%$1.45 billionN/A0.00Insider Selling
Increase in Short Interest
Endo International logo
ENDP
Endo International
1.3$6.26-3.4%$1.44 billion$2.91 billion-9.21
Cara Therapeutics logo
CARA
Cara Therapeutics
1.6$28.51-0.7%$1.42 billion$19.89 million-13.45Analyst Report
News Coverage
Theravance Biopharma logo
TBPH
Theravance Biopharma
1.6$21.71-1.0%$1.42 billion$73.41 million-4.59
Zealand Pharma A/S logo
ZEAL
Zealand Pharma A/S
1.2$32.56-0.8%$1.41 billion$6.20 million-14.28News Coverage
Zymeworks logo
ZYME
Zymeworks
1.8$30.38-0.7%$1.40 billion$29.54 million-8.06Unusual Options Activity
Cassava Sciences logo
SAVA
Cassava Sciences
0.9$34.85-0.7%$1.39 billionN/A-145.21
Aclaris Therapeutics logo
ACRS
Aclaris Therapeutics
0.8$26.68-1.3%$1.38 billion$4.23 million-19.76Increase in Short Interest
ATBPD
Antibe Therapeutics
0.1$3.57-0.3%$1.38 billion$7.51 million-5.95Gap Down
Arcutis Biotherapeutics logo
ARQT
Arcutis Biotherapeutics
1.6$27.52-4.2%$1.38 billionN/A-2.98
Keros Therapeutics logo
KROS
Keros Therapeutics
1.6$56.67-12.0%$1.32 billionN/A0.00Increase in Short Interest
COMPASS Pathways logo
CMPS
COMPASS Pathways
1.5$34.35-0.9%$1.26 billionN/A0.00Analyst Upgrade
News Coverage
Shattuck Labs logo
STTK
Shattuck Labs
1.5$30.01-5.6%$1.25 billionN/A0.00Analyst Report
Increase in Short Interest
Repare Therapeutics logo
RPTX
Repare Therapeutics
1.6$33.68-1.1%$1.25 billionN/A0.00
Dynavax Technologies logo
DVAX
Dynavax Technologies
1.7$10.99-1.2%$1.24 billion$35.22 million-8.02News Coverage
Ocular Therapeutix logo
OCUL
Ocular Therapeutix
1.6$15.89-1.6%$1.21 billion$4.23 million-8.88
Kronos Bio logo
KRON
Kronos Bio
1.7$21.56-0.7%$1.21 billionN/A0.00Insider Selling
Innoviva logo
INVA
Innoviva
1.4$11.90-0.1%$1.21 billion$261.02 million6.07
This page was last updated on 4/17/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.